REBACIN® inhibits E6/E7 oncogenes in clearance of human papillomavirus infection
Authors:
Open Access
- 6 December 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1047222
Abstract
Previous studies have demonstrated that REBACIN® intervention eliminates persistent high-risk human papillomavirus (hrHPV) infection. The initial establishment and subsequent progression of cervical cancer mainly depends on two major oncogenes, E6/E7, and previous studies have proposed E6/E7 oncogenes as a target for therapeutic drug development. The aim of this study was to investigate in vitro and in vivo whether REBACIN® inhibits E6/E7 oncogenes for elucidating the mechanism of REBACIN® in the clearance of persistent hrHPV infection. In vitro, after REBACIN® treatment, the growth of both Ca Ski and HeLa cervical cancer cells containing the E6/E7 oncogenes was prevented. In line with this finding is that E6/E7 expression was inhibited, which can be counteracted by the co-application of anti-REBACIN® antibody. These studies demonstrated that REBACIN® can effectively inhibit the growth of cervical cancer cells via targeting HPV E6/E7 expression. To further verify this finding in clinic, 108 volunteer patients with persistent hrHPV infections were randomly divided into REBACIN®, recombinant human interferon alpha-2b (Immunological drug control), or no-treatment blank control groups, received intravaginal administration of REBACIN®, interferon or no-treatment every other day for three months, and then followed up for E6/E7 mRNA assay. In REBACIN® group, 68.57% of patients showed complete clearance of HPV E6/E7 mRNA, which was significantly higher compared to 25.00% in the interferon immunological drug control group and 20.00% in blank control group, confirming that REBACIN® is potently efficacious on clearing persistent hrHPV infections via inhibition of HPV E6/E7 oncogenes.Clinical trial registration: http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100045911, identifier ChiCTR2100045911.Keywords
This publication has 39 references indexed in Scilit:
- The papillomavirus E7 proteinsVirology, 2013
- A systematic review of the prevalence of mucosal and cutaneous human papillomavirus typesVirology, 2013
- Loop Electrosurgical Excision Procedure and the Risk for Preterm DeliveryObstetrics & Gynecology, 2013
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- A review of human carcinogens—Part B: biological agentsThe Lancet Oncology, 2009
- Interferon‐inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1The EMBO Journal, 2008
- New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancerCancer Gene Therapy, 2007
- Case–Control Study of Human Papillomavirus and Oropharyngeal CancerNew England Journal of Medicine, 2007
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002
- Control of interferon signaling in human papillomavirus infectionCytokine & Growth Factor Reviews, 2001